评论“ApoE 导向疗法迅速清除β-淀粉样蛋白并逆转 AD 小鼠模型的缺陷”。

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

机构信息

Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, University of Florida College of Medicine, 1275 Center Drive, Gainesville, FL 32610, USA.

出版信息

Science. 2013 May 24;340(6135):924-d. doi: 10.1126/science.1234089.

DOI:10.1126/science.1234089

PMID:23704553

Abstract

Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrates short-term bexarotene treatment clearing preexisting β-amyloid deposits from the brains of APP/PS1ΔE9 mice with low amyloid burden, providing a rationale for repurposing this anticancer agent as an Alzheimer's disease (AD) therapeutic. Using a nearly identical treatment regimen, we were unable to detect any evidence of drug efficacy despite demonstration of target engagement.

摘要

Cramer 等人（报告，2012 年 3 月 23 日，第 1503 页；在线发表，2012 年 2 月 9 日）表明，贝沙罗汀的短期治疗能清除 APP/PS1ΔE9 小鼠大脑中低淀粉样蛋白负荷的预先存在的β-淀粉样蛋白沉积，为将这种抗癌药物重新用于治疗阿尔茨海默病（AD）提供了依据。尽管已经证明了药物靶点的结合，但我们使用了几乎相同的治疗方案，却未能检测到任何药物疗效的证据。